Therapeutic Potential

The pharmacological effects of cannabis are clinically evident. However, due to sociopolitical research hindrances, cannabis is currently only approved for a few indications (nausea and vomiting during chemotherapy, lack of appetite and cachexia in HIV or cancer, neuropathic or chronic pain and spasticity in MS). Therefore, the off-label or no-label use of non-approved cannabis pharmaceuticals is the rule, not the exception. Apparently, the therapeutic potential of cannabis is not limited to individual indications but covers symptom complexes that are important for diseases with completely different etiologies.

The therapeutically utilizable potential of cannabis and cannabinoids is clinically evident but unexplored to a large extent. In Germany cannabis-based pharmaceuticals are currently officially approved only for moderate to severe spasticity in adults with multiple sclerosis. Therefore, the off-label or no-label use of non-approved cannabis pharmaceutical is the rule.

Cannabis is mostly prescribed palliatively, meaning for the relief of symptoms.

Scientific literature (and anecdotal, not scientifically-proven experience reports, e.g. on the internet) also point to future curative as well as preventive application possibilites.1-4  

Plant cannabinoids act on the endocannabinoid system (ECS) of the body, that is fundamentally involved in the regulation of diverse functions of the central nervous system and the immune system. Moreover, the ECS also regulates cell mitosis as well as programmed cell death and influences the body’s metabolism. Hence, the therapeutic potential of cannabis is not limited to single indications but covers symptom complexes that are important for diseases with completely different etiologies and may therefore provide relief in various ailments.  

The most established indications for cannabis-based medication so far are (see table 1)

  • nausea and vomiting (e.g. due to cancer chemotherapy)5
  • lack of appetite and cachexia (e.g. in HIV or cancer)6
  • neuropathic and chronic pain and spasticity (e.g. in multiple sclerosis) 7,8.

Between 2007 and 2016, the Federal Opium Agency of Germany granted exemption permits for a physician-accompanied self-therapy with cannabis for more than 50 different indications (see table 1). 

Indication Number of studies found Total number of patients
Nausea and vomiting due to cancer-chemotherapy or radiation 33 1581
Appetite and chemosensory perception in cancer or HIV/ AIDS patients 10 973
Neuropathic or chronic pain 35 2046
Experimental or acute pain 11 387
Spasticity in Multiple Sclerosis 14 1740
Tremor in Multiple Sclerosis 2 22
Bladder dysfunction in Multiple Sclerosis 2 765
Disease Progression, inflammation and cognitive impairment in Multiple Sclerosis 3 610
Paraplegia 3 10
Tourette-Syndrome 2 36
Epilepsy 1 15
Glaukoma 3 32
Dystonia 1 15
Intestinal Dysfunction and irritable bowel 5 215
Morbus Crohn 1 21
Diseases of the respiratory tract 1 9
Problematic cannabis use 2 207
Anxiety and PTSD 4 104
Schizophrenia 2 55
Morbus Parkinson 3 47
Dementia 1 50
Cannabinoid interactions 2 58
Total 140 ca. 8000
Table 1: Number of controlled clinical trials with Cannabis-based drugs between 1975 and 2015

Symptoms and diseases for which the BfArm granted exemption permits for the accompanied self-therapy with cannabis (see table 2.)

General symptom in the following diseases
Nausea and vomiting Cancer chemotherapy, HIV/AIDS, Hepatitis C, hyperemesis gravidarium, migraine
Anorexia and cachexia HIV/ AIDS, advanced cancer, Hepatitis C
Spasticity, Spasms, Muscle stiffness Multiple Sclerosis, paraplegia, spasticity after stroke, tension headache, spinal syndromes
Hyperkinetic dyskinesia Tourette-syndrome, dystonia (spastic torticollis or blepharospasm, etc.), Levodopa-induced dyskinesia, tardive dyskinesia, essential tremor, Morbus Parkinson
Pain Migraine, cluster headache, phantom pains, neuralgia, menstrual pain, paresthesia in diabetes mellitus or AIDS, hyperalgesia, hypertonic muscle /spasms, arthrosis, arthritis, colitis ulcerosa, restless legs syndrome, fibromyalgia
Allergies Allergic asthma, hay fever
Pruritus Disorders of the liver, neurodermatitis
Chronic-inflammatory diseases Asthma, arthritis, colitis ulcerosa, Morbus Crohn, Neurodermatitis, Morbus Bechterew, Psoriasis
Psychological disorders Psychological disorders Depression, anxiety, bipolar disorders, PTSD, AD(H)S impotence, addiction to alcohol, opiates and benzodiazepines, insomnia, autism, confused behavior in Alzheimer‘s
Overproduction of gastric acid Gastritis, reflux
Heightened intraocular pressure Glaucoma
Sensory Tinnitus
As bronchodilator Asthma, COPD
Epilepsia
Singultus
Skin disorders Neurodermatitis, Psoriasis, Akne inversa, Hyperhidrosis
Colon irritable
Table 2. Symptoms and diseases for which the BfArm granted exemption permits for the accompanied self-therapy with cannabis (from Cannabis: Verordnungshilfe für Ärzte. Grotenhermen, Häußermann)
Share on facebook
Share on twitter
Share on pinterest
Share on email
Share on print

[1] Cabral GA, Rogers TJ, Lichtman AH. Turning Over a New Leaf: Cannabinoid and Endocannabinoid Modulation of Immune Function. J Neuroimmune Pharmacol. 2015;10(2):193-203. doi:10.1007/s11481-015-9615-z

[2] Blasco-Benito S, Seijo-Vila M, Caro-Villalobos M, et al. Appraising the “entourage effect”: Antitumor action of a pure cannabinoid versus a botanical drug preparation in preclinical models of breast cancer. Biochem Pharmacol. June 2018. doi:10.1016/j.bcp.2018.06.025

[3] Liang C, McClean MD, Marsit C, et al. A Population-Based Case-Control Study of Marijuana Use and Head and Neck Squamous Cell Carcinoma. Cancer Prev Res. 2009;2(8):759-768. doi:10.1158/1940-6207.CAPR-09-0048

[4] Dumitru CA, Sandalcioglu IE, Karsak M. Cannabinoids in Glioblastoma Therapy: New Applications for Old Drugs. Front Mol Neurosci. 2018;11:159. doi:10.3389/fnmol.2018.00159

[5]Tramèr MR, Carroll D, Campbell FA, Reynolds DJ, Moore RA, McQuay HJ. Cannabinoids for control of chemotherapy induced nausea and vomiting: quantitative systematic review. BMJ. 2001;323(7303):16-21. http://www.ncbi.nlm.nih.gov/pubmed/11440936. Accessed July 27, 2018.

[6] Badowski ME, Yanful PK. Dronabinol oral solution in the management of anorexia and weight loss in AIDS and cancer. Ther Clin Risk Manag. 2018;14:643-651. doi:10.2147/TCRM.S126849

[7] Sharon H, Goldway N, Goor-Aryeh I, Eisenberg E, Brill S. Personal experience and attitudes of pain medicine specialists in Israel regarding the medical use of cannabis for chronic pain. J Pain Res. 2018;11:1411-1419. doi:10.2147/JPR.S159852

[8] Zajicek JP, Hobart JC, Slade A, Barnes D, Mattison PG, MUSEC Research Group on behalf of the MR. Multiple sclerosis and extract of cannabis: results of the MUSEC trial. J Neurol Neurosurg Psychiatry. 2012;83(11):1125-1132. doi:10.1136/jnnp-2012-302468

Cannabis: Verordnungshilfe für Ärzte von Franjo Grotenhermen; Klaus Häußermann – ISBN 10: 3804737595 – ISBN 13: 9783804737594